These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33657863)

  • 1. Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.
    Berlie HD; Kale-Pradhan PB; Orzechowski T; Jaber LA
    Ann Pharmacother; 2021 Nov; 55(11):1386-1396. PubMed ID: 33657863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study.
    Pérez-Belmonte LM; Torres-Peña JD; López-Carmona MD; Ayala-Gutiérrez MM; Fuentes-Jiménez F; Jorge Huerta L; Muñoz JA; Rubio-Rivas M; Madrazo M; Garcia MG; Montes BV; Sola JF; Ena J; Ferrer RG; Pérez CM; Ripper CJ; Lecumberri JJN; Acedo IEA; Canteli SP; Cosío SF; Martínez FA; Rodríguez BC; Pérez-Martínez P; Ramos-Rincón JM; Gómez-Huelgas R;
    BMC Med; 2020 Nov; 18(1):359. PubMed ID: 33190637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DPP-4 inhibition and COVID-19: From initial concerns to recent expectations.
    Scheen AJ
    Diabetes Metab; 2021 Mar; 47(2):101213. PubMed ID: 33249199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in glucose-lowering medication regimens in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
    Jacob L; Rickwood S; Rathmann W; Kostev K
    Diabetes Obes Metab; 2021 Apr; 23(4):910-915. PubMed ID: 33319440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-lowering drugs and outcome from COVID-19 among patients with type 2 diabetes mellitus: a population-wide analysis in Hong Kong.
    Luk AOY; Yip TCF; Zhang X; Kong APS; Wong VW; Ma RCW; Wong GL
    BMJ Open; 2021 Oct; 11(10):e052310. PubMed ID: 34670765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
    Fass AD; Gershman JA
    Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
    Pinheiro MM; Fabbri A; Infante M
    Immunotherapy; 2021 Jun; 13(9):753-765. PubMed ID: 33906375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 - A systematic review and meta-analysis.
    Zein AFMZ; Raffaello WM
    Prim Care Diabetes; 2022 Feb; 16(1):162-167. PubMed ID: 34952805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
    Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
    Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection.
    Bielka W; Przezak A; Pawlik A
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE; Salsali A
    Curr Med Res Opin; 2007 Apr; 23(4):919-31. PubMed ID: 17407649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
    Schernthaner G
    Diabetes Metab J; 2021 Jul; 45(4):615-616. PubMed ID: 34352990
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19 (Diabetes Metab J 2021;45:251-9).
    Rhee SY
    Diabetes Metab J; 2021 Jul; 45(4):619-620. PubMed ID: 34352992
    [No Abstract]   [Full Text] [Related]  

  • 16. Metformin and COVID-19: From cellular mechanisms to reduced mortality.
    Scheen AJ
    Diabetes Metab; 2020 Nov; 46(6):423-426. PubMed ID: 32750451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
    Boland CL; Degeeter M; Nuzum DS; Tzefos M
    Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes, Drug Treatment, and Mortality in COVID-19: A Multinational Retrospective Cohort Study.
    Nyland JE; Raja-Khan NT; Bettermann K; Haouzi PA; Leslie DL; Kraschnewski JL; Parent LJ; Grigson PS
    Diabetes; 2021 Dec; 70(12):2903-2916. PubMed ID: 34580086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial.
    Santamarina M; Carlson CJ
    BMC Cardiovasc Disord; 2019 Mar; 19(1):60. PubMed ID: 30876392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
    Guthrie RM
    Postgrad Med; 2015 Jun; 127(5):463-79. PubMed ID: 25956345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.